Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84182 trials found · Page 9 of 4210
-
Scientists launch bold attack on rare, deadly 'Mixed' leukemia
Disease control Not yet recruitingAcute leukemia of ambiguous lineage (ALAL), which refers to acute leukemia without definite evidence indicating cell differentiation along a specific lineage, mainly encompasses two major categories: acute undifferentiated leukemia (AUL) lacking the expression of lineage-specific…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
Major trial launches for aggressive stomach cancers
Disease control Not yet recruitingGastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). …
Phase: PHASE3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
Major trial aims to boost survival for kids with aggressive blood cancers
Disease control Not yet recruitingThis phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune ce…
Phase: PHASE2, PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Major trial launches for Tough-to-Treat ovarian cancer
Disease control Not yet recruitingThis study specifically aims to evaluate how well GSK5733584 works in treating ovarian cancer compared to standard treatments. The study also assesses whether GSK5733584 is safe and tolerated well by participants compared to standard treatments and aims to provide a better unders…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New gene therapy trial aims to reboot immune system against tough cancers
Disease control Not yet recruitingThis phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug trial offers hope for Tough-to-Treat bladder cancer
Disease control Not yet recruitingThis study is a randomized, controlled, open-label, multicenter phase III clinical trial, which aims to evaluate the efficacy,safety PK characteristics, and immunogenicity of SYS6002 compared with chemotherapy in participants with locally advanced or metastatic urothelial carcino…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New pill offers hope for kids with rare bone disease, could replace chemo
Disease control Recruiting nowLangerhans cell histiocytosis (LCH) is the most common type of histiocytic disorder in children, affecting about 2.6 to 8.9 out of every million kids each year. It can look very different from one child to another-some cases get better on their own-but when it affects special bon…
Phase: NA • Sponsor: West China Second University Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New injection could replace IV drips for leukemia patients
Disease control Not yet recruitingThe main objective of this trial is to demonstrate that subcutaneous (SC) blinatumomab in conjunction with chemotherapy (Arm B) is non-inferior to continuous intravenous infusion (cIV) blinatumomab in conjunction with chemotherapy (Arm A) in overall survival (OS) in newly diagnos…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 13, 2026 20:08 UTC
-
Gut bacteria pill aims to supercharge cancer fight
Disease control Not yet recruitingThis phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell c…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New hope for advanced endometrial cancer: major trial tests promising drug
Disease control Not yet recruitingThis study specifically aims to evaluate how well GSK5733584 works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether GSK5733584 is safe and tolerated well by participants in comparison to standard of care and will help provide a bet…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Pulsed radiation trial aims to outsmart deadly brain tumor
Disease control Not yet recruitingThis phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma. After completion of surgery, the standard of care for glioblastoma is radiation t…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC
-
Major cancer trial pits new drug against established treatment
Disease control Not yet recruitingThe purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Major trial aims to improve First-Line treatment for blood cancer
Disease control Not yet recruitingThis study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT). This study is evaluating a drug called linvoseltamab in combination with standard therapies for…
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Major trial launches for deadly pancreatic cancer treatment
Disease control Not yet recruitingCancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these du…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC
-
Double-Punch treatment tested for kids with Tough-to-Treat blood cancers
Disease control Recruiting nowThe purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL. Primary Objective: \- To assess the safety and feasibility of combining CD19-CAR(Mem) …
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:19 UTC
-
Targeted radiation and transplant tested for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis phase I trial investigates the side effects and best dose of ²¹¹At-OKT10-B10 when given together with fludarabine, alone or in combination with cyclophosphamide and low-dose total-body irradiation (TBI) before donor stem cell transplant in treating patients with high-risk mu…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
New stroke procedure aims to prevent second clots
Disease control Not yet recruitingThe study objective is to establish the safety and efficacy of endovascular adjunct stenting for patients undergoing mechanical thrombectomy (MT) that are found to have residual stenosis (70-99%) following attempted clot retrieval with either aspiration catheters or stent retriev…
Phase: PHASE3 • Sponsor: ProMedica Health System • Aim: Disease control
Last updated Apr 21, 2026 10:14 UTC
-
Groundbreaking psychedelic trial offers new hope for veterans with severe depression
Disease control Not yet recruitingThe purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
Phase: PHASE3 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
New CAR T-Cell therapy aims to stop lymphoma in its tracks before it returns
Disease control Not yet recruitingThe goal of the main clinical research study is to learn if treatment with a chimeric antigen receptor (CAR) T-cell therapy called lisocabtagene maraleucel (liso-cel) can help to prevent recurrence of large B-cell cell lymphoma in patients who have achieved complete response (CR)…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
Scientists test 'Living Drug' to fight incurable blood cancer
Disease control Not yet recruitingA Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.
Phase: EARLY_PHASE1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC